Research reveals that astrocytic PAD2 drives microglial dysfunction in Alzheimer's disease, suggesting a new treatment pathway.
Zhang et al. reveal that astrocytic PAD2-mediated citrullination of vimentin drives a TLR4-dependent pro-inflammatory loop in microglia, linking glial crosstalk to impaired amyloid clearance and identifying a potential therapeutic and biomarker pathway in Alzheimer’s disease.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: